Abstract
PET/CT images provide a rich data source for clinical prediction models in head and neck squamous cell carcinoma (HNSCC). Deep learning models often use images in an end-to-end fashion with clinical data or no additional input for predictions. However, in the context of HNSCC, the tumor region of interest may be an informative prior in the generation of improved prediction performance. In this study, we utilize a deep learning framework based on a DenseNet architecture to combine PET images, CT images, primary tumor segmentation masks, and clinical data as separate channels to predict progression-free survival (PFS) in days for HNSCC patients. Through internal validation (10-fold cross-validation) based on a large set of training data provided by the 2021 HECKTOR Challenge, we achieve a mean C-index of 0.855 ± 0.060 and 0.650 ± 0.074 when observed events are and are not included in the C-index calculation, respectively. Ensemble approaches applied to cross-validation folds yield C-index values up to 0.698 in the independent test set (external validation). Importantly, the value of the added segmentation mask is underscored in both internal and external validation by an improvement of the C-index when compared to models that do not utilize the segmentation mask. These promising results highlight the utility of including segmentation masks as additional input channels in deep learning pipelines for clinical outcome prediction in HNSCC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
M.A.N. is supported by a National Institutes of Health (NIH) Grant (R01 DE028290-01). K.A.W. is supported by a training fellowship from The University of Texas Health Science Center at Houston Center for Clinical and Translational Sciences TL1 Program (TL1TR003169), the American Legion Auxiliary Fellowship in Cancer Research, and a NIDCR F31 fellowship (1 F31 DE031502-01). C.D.F. received fund-ing from the National Institute for Dental and Craniofacial Research Award (1R01DE025248-01/R56DE025248) and Academic-Industrial Partnership Award (R01 DE028290), the National Science Foundation (NSF), Division of Mathematical Sciences, Joint NIH/NSF Initiative on Quantitative Approaches to Biomedical Big Data (QuBBD) Grant (NSF 1557679), the NIH Big Data to Knowledge (BD2K) Pro-gram of the National Cancer Institute (NCI) Early Stage Development of Technolo-gies in Biomedical Computing, Informatics, and Big Data Science Award (1R01CA214825), the NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148), the NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672), the NIH/NCI Head and Neck Specialized Programs of Research Excellence (SPORE) Developmental Re-search Program Award (P50 CA097007) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Program (R25EB025787). He has received direct industry grant support, speaking honoraria and travel funding from Elekta AB.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data was used with approval from the HECKTOR Challenge organizers. Institutional Review Boards (IRB) of all participating institutions permitted the use of images and clinical data, either fully anonymized or coded, from all cases for research purposes, only. Retrospective analyses were performed following the relevant guidelines and regulations as approved by the respective institutional ethical committees with protocol numbers: MM-JGH-CR15-50 (HGJ, CHUS, HMR, CHUM) and CER-VD 2018-01513 (CHUV).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
manaser{at}mdanderson.org
Data Availability
Data are available from the MICCAI HECKTOR 2021 Challenge Organizers.